Ray Wakefield
Nurse Practitioner · Brownsville, TNNPI 1184055345
Payments from drug & device makers
Across 544 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$983
- Novo Nordisk$954
- AstraZeneca$884
- AbbVie$831
- Takeda Pharmaceuticals U.S.A., Inc.$704
- Pfizer$570
- plus $4K from 33 others
What the payments were for
- Food & beverage$8,820100%
- Education$420%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$134
- FARXIGA$134
- INJECTAFER$123
How this compares
$8,861 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 42 | $40,380 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $39,274 |
| MounjaroTirzepatide | 27 | $27,299 |
| FarxigaDapagliflozin Propanediol | 32 | $27,036 |
| OzempicSemaglutide | 16 | $17,154 |
| LinzessLinaclotide | 20 | $16,117 |
| EliquisApixaban | 12 | $15,451 |
| RybelsusSemaglutide | 11 | $13,790 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $13,572 |
| JanuviaSitagliptin Phosphate | 15 | $13,398 |
| XareltoRivaroxaban | 18 | $13,382 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $11,542 |
| SynjardyEmpagliflozin/Metformin Hcl | 12 | $11,481 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,677 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $3,074 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy | $983 | $51,86154 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $431 | $45,95162 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $884 | $38,57846 claims |
| Novo NordiskOzempic, Rybelsus | $954 | $30,94327 claims |
| Lilly USA, LLCMounjaro | $563 | $27,29927 claims |
| MerckJanumet Xr, Januvia | $352 | $26,97032 claims |
| AbbVieLinzess | $831 | $16,11720 claims |
| PfizerEliquis | $570 | $15,45112 claims |
| Johnson & JohnsonXarelto | $242 | $13,38218 claims |
| Sanofi-aventis U.S. LLCLantus | $111 | $97114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Brownsville
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
- Susan UtleyNashville$194K
- Whitney EricksonMemphis$159K
- Erica HembreeKnoxville$125K
- Brooke FaughtNashville$89K
- Lauren WelchNashville$71K
- Cara StoutKingsport$71K
- S Marie HamiltonOoltewah$64K
- Cynthia WilsonChattanooga$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.